Introduction
The first emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
in 2019 has led to the COVID-19 pandemic with millions of infections and deaths
worldwide. Even two years after the onset of the pandemic, the long-term
consequences for the population and population development are still difficult to
estimate. The potential effects of COVID-19 on reproduction are of particular
interest in this context.
Endocrine, genetic, physiological, and psychological factors as well as social and
lifestyle habits, such as smoking and alcohol consumption, influence human
fertility. During the COVID-19 pandemic, several additional factors may affect
fertility, including: (1) the biological effects of a COVID-19 infection on gonads;
(2) the effects of COVID-19 on mental health; (3) the effects of the COVID-19
pandemic on sexual behaviour (
Fig. 1
). The
COVID-19 pandemic has also been associated with a decline in sexual satisfaction,
reported by 44.5% of participants in a study (1314 responses of health
professionals, mean age: 37 years), which included the following factors: lower
libido, lack of nightlife, higher frequency of masturbation, and isolation from
partner
1
. Polish women (n=1644)
reported a lower frequency of sexual activity and a lower libido during the pandemic
than before
2
. However, another study showed
that the average frequency of sexual intercourse was significantly increased during
the pandemic compared to 6–12 months before
3
. There are also claims that the ongoing pandemic might result in a
“baby boom”, since couples spend more time with each other
4
.
Potential factors that may affect fertility in females and
males during the COVID-19 pandemic:
a
: SARS-CoV-2 virus entry is
highly dependent on the expression of angiotensin-converting enzyme 2 (ACE2)
and transmembrane protease serine subtype 2 (TMPRSS2) and a simultaneous
expression in human gonads could cause local inflammation after virus entry
leading to tissue dysfunction.
b
: Physiological stress during the
ongoing pandemic may also have an impact on the libido and the menstrual
cycle.
c
: The interaction between the hypothalamic-pituitary-gonadal
(HPG) axis and the hypothalamic-pituitary-adrenal (HPA) axis plays a crucial
role in human fertility, and a possible imbalance caused by SARS-CoV-2
infection could affect fertility in the short and/or long term. ADH:
Antidiuretic hormone; ACTH: Adrenocorticotropic hormone; CRH:
Corticotropin-releasing hormone; FSH: Follicle-stimulating hormone; GnRH:
Gonadotropin-releasing hormone; LH: Luteinizing hormone.
The hypothalamic-pituitary-gonadal (HPG) axis is mediated by the release of
gonadotropin-releasing hormone (GnRH) from the hypothalamus as response to
diminished levels of circulating sex hormones, oestrogens in females and
testosterone in males (
Fig. 1
)
5
. GnRH stimulates the production of
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in the anterior
pituitary. In males, LH targets Leydig cells and FSH acts on the Sertoli cells in
the testis causing the synthesis of testosterone responsible for spermatogenesis
6
. In females, FSH stimulates follicle
development and oestrogen production, while LH causes ovulation and further
stimulates progesterone and oestrogen production
7
. Impairment of the HPG axis thus has direct consequences for fertility
in males and females (
Fig. 1
). The
interaction between the hypothalamic-pituitary-adrenal (HPA) axis, which integrates
internal and external stress response, and the HPG axis may also contribute to
possible effects of COVID-19 infections on human fertility (
Fig. 1
). In response to stress, the adrenal
glands secrete glucocorticoids such as cortisol that diminish LH release in the
pituitary and sex hormone production in the gonads
8
. This is particularly important, as glucocorticoids such as
dexamethasone are the most commonly used therapeutic approach to limit the
progression of severe COVID-19 and inflammation
9
10
and exogenous glucocorticoid
administration is well known to cause temporary impairment of fertility
11
.
In the present review, we examine possible entry pathways of SARS-CoV-2 virus into
human gonads and the current knowledge of subsequent COVID-19 infection and its
short- and possible long-term effects on human fertility.
SARS-CoV-2 virus entry is highly dependent on the co-expression of
angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine subtype
2 (TMPRSS2) on the surface of the target cell
12
. In addition to an age- and sex-dependent expression of both
enzymes, the expression is dependent on the respective tissue and is thus
directly involved in the virus vulnerability of specific tissues
13
14
.
The testis is one of the organs with high constitutive expression of ACE2 due to
its physiological functions in Leydig cells, including the regulation of
testosterone production and balancing the local vascular regulatory system by
the modulation of Angiotensin II to Angiotensin I conversion
15
16
17
. ACE2 and TMPRSS2
proteins are predominantly expressed in the cytoplasm and membrane of
spermatocytes, spermatids, and Sertoli cells; increased levels of ACE2 and
TMPRSS2 have been observed in testicular tubules in elder patients with COVID-19
18
. Testicular mRNA levels of
ACE2
and
TMPRSS2
also increase in COVID-19 patients
18
. Another study including also younger
men (32–88 years) confirmed expression of
ACE2
in Sertoli cells,
spermatogonia, fibroblasts, and Leydig cells
19
. Our own data showed an equally strong ACE2 expression in the
testicular tubuli and interstitium (
Fig.
2
). Single-cell RNA sequencing indicates that
ACE2
is
predominantly enriched in spermatogonia and Leydig and Sertoli cells
20
. Gene Ontology (GO) categories
associated with viral reproduction and transmission are highly enriched in
ACE2
-positive spermatogonia, while male gamete generation-related
terms are downregulated
20
. ACE2
expression in normal testis cells decreased with increasing age
21
. Male gonads constitute a potential
target tissue for SARS-CoV-2.
Differential ACE2 expression in ovary and testis:
a
:
Representative histology from the ovary of an 87-year-old patient who
died from SARS-CoV-2 infection and revealed detectable SARS-CoV-2-RNA
(not shown) in post-mortem ovarian tissue at autopsy. Immunostaining for
ACE2 shows a prominent expression in ovarian stromal cells of hilus
(left side of the image) and a weak expression in some cortical stromal
cells (right side of the image).
b
: Representative histology from
the testis of a 56-year-old patient who died from SARS-CoV-2 infection.
The background shows a conventional HE-stain of the autopsy sample.
Immunostaining for ACE2 demonstrates a strong expression in all cellular
elements of the tubuli (Sertoli and spermatogonia, left side of the
image) and a middle-strong expression in the Leydig cells in the
testicular interstitium (right side of the image).
The ovaries are the core of the female reproduction system, and cell damage, for
example, caused by SARS-CoV-2 infection, or pathologies such as endometriosis
can lead to infertility. A co-expression of ACE2 and TMPRSS2 was observed
predominantly in oocytes and partially in granulosa cells
22
. Our research revealed a dominant ACE2
expression in ovarian hilus and minimal expression in ovarian cortex (
Fig. 2
). No differences in the expression
of
ACE2
and
TMPRSS2
in the ovaries were found in dependence on age
22
. The abundant expression of ACE2
in the female reproductive system is associated with the generation of
angiotensin (1–7) which stimulates ovarian follicle growth, oocyte
maturation and ovulation
23
. In rats,
ACE2 expression and activity are increased during pregnancy, in particular in
the placenta and the uterus
24
. However,
ACE2 expression appears to be lower in the human ovaries than in the testis
(
Fig. 2
), which may indicate a
higher susceptibility of the male gonads for SARS-CoV-2 than the female
gonads.
In addition to ACE2 and TMPRSS2, there is emerging evidence that SARS-CoV-2 uses
DPP4 (also known as cluster of differentiation 26) as co-receptor during host
cell entry
25
26
. Single-cell RNA sequencing reveals
expression of
DPP4
in the human testis (spermatogonia and spermatogonial
stem cell) and ovaries (predominantly endothelial cells)
27
. Besides
ACE2
and
TMPRSS2
,
DPP4
is also expressed in the human placenta
28
. DPP4 expression also plays an
important role in polycystic ovary syndrome (PCOS), which is a common hormonal
dysfunction among women of reproductive age (prevalence of 5–20%
in women) characterised by abnormal androgen levels associated with the
appearance of numerous small cysts formed in the ovaries
29
. PCOS is associated with infertility
and increased risk for type 2 diabetes, venous thromboembolism, cerebrovascular
and cardiovascular events, and endometrial cancer
29
. Young age and female sex are normally
associated with a lower risk of severe or even fatal COVID-19
30
, but female patients with PCOS present
a distinct subgroup of women with a potentially higher risk for adverse COVID-19
outcomes
31
. A population-based cohort
study revealed an increased COVID-19 infection rate in women with PCOS compared
with age and general practice matched control women
32
. Androgens regulate transcription of
TMPRSS2
and
DPP4
33
,
which may contribute to the higher SARS-CoV-2 infection rates in women with
PCOS. In addition, the increased rates of comorbidities including type 2
diabetes and cardiovascular disease may contribute to the severity in these
patients. DPP4 inhibitors, commonly used in people with diabetes, diminish
levels of free androgens in patients with PCOS and affect innate immune response
34
35
, which may also be beneficial in the context of COVID-19,
especially in patients with PCOS.
DPP4 expression was detected in several testicular peritubular cells and cells of
the interstitial space indicating a potential impact on spermatogenesis
36
. In rats, DPP4 inhibitors vildagliptin,
and sitagliptin showed promise in protecting against testicular
torsion/detorsion-induced injury through an anti-inflammatory effect
augmented by nitric oxide synthase inhibition
37
. The expression of DPP4 in human gonads, which may be increased
by various medical conditions such as PCOS, provides further evidence that the
gonads may be a potential target for SARS-CoV-2.
Viral diseases such as hepatitis B and Zika virus infection have already been
linked to impaired fertility in women
38
. There is also indirect evidence that SARS-CoV-2 might affect female
fertility by engaging ovarian tissue and granulosa cells, thereby diminishing
oocyte quality and ovarian function
39
.
However, a cohort autopsy study failed to detect SARS-CoV-2 in the ovaries
(n=7)
40
. Endometrial epithelial
cells might also be infected due to the expression of ACE2, which might affect
early embryo implantation
41
. In an
observational, single-centre study including 78 females of reproductive age,
ovarian injury, including declined ovarian reserve and reproductive endocrine
disorder, was observed in women infected with COVID-19
42
. Another retrospective cohort study
found no evidence that a history of SARS-CoV-2 infection in females may
negatively affect female fertility, embryo laboratory outcomes, or clinical
outcomes in assisted reproductive technology treatments
43
. Long-term sequelae of COVID-19
infection affecting female fertility have been described in a few isolated cases
(see long COVID section). Not only COVID-19 infection itself can affect female
fertility, but psychological stress during the pandemic may also have
consequences. In a survey study (1031 females), 46% of the participants
reported a change in their menstrual cycle, and 53% reported worsening
of premenstrual symptoms since the onset of the COVID-19 pandemic
44
. Menstrual disorders seem to be
generally more common during the pandemic than before
3
. Female fertility is affected by a
variety of factors, and current data do not provide sufficient evidence to
determine whether infection with SARS-CoV-2 can temporarily or even permanently
impair female fertility.
Various viruses including Ebola virus, Zika virus and cytomegalovirus have been
reported in human semen, among these some can affect male fertility
45
46
. Moreover, viruses such as HIV, mumps, hepatitis B and C,
papilloma-family (HPV) and Epstein–Barr (EBV) as well as SARS-CoV (2002)
are described to cause viral orchitis
47
. The testis is among the few organs with immune privilege, which
allows them to remain intact and unaffected by host response to antigen
introduction
48
. This may explain why
proteome analysis in testes of COVID-19 patients revealed only a small number of
differentially expressed proteins compared with non-infected samples, whereas
other organ types showed much more changes when infected with SARS-CoV-2
49
. All of the identified proteins were
downregulated compared with the non-COVID-19 infected controls (
ACLY
,
FASN
,
SQLE
,
FDFT1
,
INSL3
,
FAM83F
,
RNF216
,
DRC7
,
TM7SF2
,
SARAF
)
49
.
Theoretically, SARS-CoV-2 may affect the male reproductive system in a number of
ways by altering: (a) testicular architecture; (b) reproductive hormone profile;
(c) spermatogenesis (ejaculate quality); (d) sperm function; (e)
sexual/erectile function; (f) a combination of the former
50
. A prospective cohort study indicates
that COVID-19 infection may be accompanied by a short-term decline in fertility
in men
51
. Histopathological
examinations on testicular and epididymal specimens of COVID-19 patients
revealed the presence of interstitial edema, congestion, red blood cell
exudation in testes, and epididymides
52
. The number of apoptotic cells within seminiferous tubules was
significantly increased and the concentration of CD3
+
or
CD68
+
interstitial cells of the testicular tissue was
enhanced in sections of COVID-19 patients compared to control cases
52
. Nevertheless,
CD3
+
and CD68
+
positive cells are also
present in epididymides under physiological conditions and play there a role in
phagocytosis
53
. An autopsy-based study
on COVID-19 positive patients demonstrated the presence of SARS-CoV-2 RNA in
47% of examined testicles
54
. In
another study, infection with SARS-CoV-2 has been detected post-mortem in 3 of
12 testicular specimens
40
. Hematoxylin
and eosin staining revealed a normal spermatogenesis in three COVID-19 positive
men, whereas spermatogenesis was impaired in three COVID-19 positive men with
elevated ACE2 levels
55
.
These data suggest an impairment of spermatogenesis in COVID-19 patients, which
might be explained in part by an enhanced immune response in the testes. A
prospective cohort study including 120 Belgian men who had recovered from
COVID-19 showed that semen were not infectious with SARS-CoV-2 one week or more
(mean 53 days) after infection, but the sperm quality was partly suboptimal
56
. This is in contrast to another
group that detected SARS-CoV-2 in semen of COVID-19 patients (6 out of 38),
including recovered patients (2 out of 23)
57
. In another study, eight out of 12 patients infected with
COVID-19 had normal semen quality
58
. A
study comparing 81 reproductive-aged men with SARS-CoV-2 infection found that
serum LH was significantly increased, but the ratio of testosterone to LH and
the ratio of FSH to LH were dramatically decreased compared to age-matched
healthy men (n=100)
59
. The
authors also confirmed these findings in a larger cohort
58
, which may also have implications for
the fertility of men infected with SARS-CoV-2. Fever, a symptom observed in many
patients infected with COVID-19, can induce oligozoospermia and apoptosis, which
may also alter sperm parameters even in absence of an enhanced immune response
in the testes
60
61
. Potential confounding factors, such as
the age of the male infected with SARS-CoV-2, could have an additional effect on
sperm quality
62
, which were only
partially considered in the present studies. The ability to detect SARS-CoV-2 in
seminal fluid is further of great importance for reproductive medicine,
particularly for reproductive technology and sperm cryopreservation
63
, since viruses stored in liquid
nitrogen could retain their pathogenic potential
64
. The exact mechanism and full extent of
how SARS-CoV-2 may affect male fertility remain unclear and extensive
prospective studies are needed to fully address these questions.
COVID-19 vaccines are the most effective tool to protect against severe COVID-19
infections and to combat the current pandemic, but some individuals of
reproductive age remain unvaccinated against SARS-CoV-2 due to concerns about
potential adverse effects on fertility. Clinical trials for COVID-19 vaccines
approved in the UK (Pfizer/BioNTech, Moderna, AstraZeneca) revealed no
difference in the rate of unintended pregnancies in the vaccinated groups
compared with the non-vaccinated groups, which indicates that the vaccines do
not prevent pregnancies
65
. A small
study showed that neither SARS-CoV-2 infections nor BNT162b2 mRNA vaccine
(Pfizer/BioNTech) altered ovarian follicular function compared with
uninfected and unvaccinated women
66
.
Moreover, mRNA based SARS-CoV-2 vaccines do not appear to induce differences in
ovarian stimulation and embryological variables between in vitro fertilisation
cycle
39
. Some studies report menstrual
cycle changes, including small changes in cycle length in some individuals after
COVID-19 vaccinations
67
68
69
, but these changes normalised rapidly after vaccination.
Moreover, a study in rats found no adverse effects of BNT162b2 on female
fertility or reproduction
70
.
Two studies investigated the effects of BNT162b2 and mRNA-1273 (Moderna)
vaccination on sperm parameters and found no differences in the sperm
concentration, semen volume, sperm motility, and total number of motile sperm
71
72
. A prospective cohort study suggests that SRAS-CoV-2 infection
may be associated with a short-term decline in fertility in men, whereas no
differences were observed in women or after COVID-19 vaccination in either sex
51
. Available data do not indicate
adverse effect of currently available vaccines on female and male fertility,
thus providing a safe route out of the current COVID-19 pandemic.
A substantial proportion of patients who have recovered from COVID-19 continue to
suffer from various complications known as long COVID or post-COVID-19 syndrome.
Nonspecific, persistent symptoms that were associated with long COVID include
chronic fatigue, muscle weakness, weakness, sleep disturbances, anxiety, and
depression
73
74
, but only little is known about
potential long-term effects on reproduction after overcoming a SARS-CoV-2
infection. A case report described a 34-year-old woman who had already given
birth to one child and now presented with infertility 12 months after her
COVID-19 infection as a long COVID consequence
75
. In another case, a 34-year-old woman suffered from premature
ovarian insufficiency with high gonadotropin levels and a very low progesterone
level of 0.3 nmol/l after COVID-19 infection
76
. After her SARS-CoV-2 infection, she
was referred to a long-COVID clinic due to persistent fatigue and continuing
myalgia. Moreover, her menstrual cycle became irregular with oligomenorrhea and
she began to have regular hot flashes and night sweats
76
. In males, an immunohistochemical study
demonstrated the presence of COVID-19 virus particles in in the penis long after
the infection
77
. Moreover, expression
of endothelial nitric oxide synthase, a marker of endothelial function was
decreased in men previously infected with COVID-19 compared to non-infected
control men
77
. As a consequence
erectile dysfunction may occur and is further favoured by other factors that may
be associated with long COVID, such as endocrine and cardiovascular
complications, stress and potential side effects of treatments
78
. Even six months after recovery from an
acute COVID-19 infection, malformed sperms were still detected in one patient
79
. A prospective longitudinal
cohort study including 84 males with confirmed COVID-19 and 105 healthy controls
found significant impairment in sperm morphology, sperm concentration, semen
volume and the number of spermatozoa in COVID-19 patients up to 60 days
post-infection
80
. As a further
long-term consequence after COVID-19 anorgasmia was described in two male
patients
81
. In terms of long COVID, not
only organ-dependent influences on reproduction should be considered, but also
psychological factors, such as depression and sleep disturbance
82
83
, which may have adverse effects on sexuality.